The Kaposi Sarcoma drugs in development market research report provides comprehensive information on the therapeutics under development for Kaposi Sarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Kaposi Sarcoma. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Kaposi Sarcoma and features dormant and discontinued products.

GlobalData tracks 25 drugs in development for Kaposi Sarcoma by 24 companies/universities/institutes. The top development phase for Kaposi Sarcoma is phase ii with 11 drugs in that stage. The Kaposi Sarcoma pipeline has 24 drugs in development by companies and one by universities/ institutes. Some of the companies in the Kaposi Sarcoma pipeline products market are: Bristol-Myers Squibb, Philogen and Tumorend.

The key targets in the Kaposi Sarcoma pipeline products market include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1), Tubulin , and Interleukin 12 Receptor (IL12R).

The key mechanisms of action in the Kaposi Sarcoma pipeline product include Tubulin Inhibitor with three drugs in Preclinical. The Kaposi Sarcoma pipeline products include 14 routes of administration with the top ROA being Intravenous and eight key molecule types in the Kaposi Sarcoma pipeline products market including Small Molecule, and Fusion Protein.

Kaposi Sarcoma overview

Kaposi’s sarcoma is a cancer that causes patches of abnormal tissue to grow under the skin; in the lining of the mouth, nose, and throat; or in other organs. Symptoms include patches that are usually red or purple and are made of cancer cells and blood cells. Lesions that develop in the stomach and intestines can cause abdominal pain and diarrhea.

For a complete picture of Kaposi Sarcoma’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.